가족성 지중해열 치료제 시장 보고서(2026년)

Pharmaceuticals for familial Mediterranean fever (FMF) are medications used to manage and treat FMF, a genetic disorder marked by recurrent fever and inflammation, frequently impacting the abdomen, chest, and joints. The main objective of these medications is to lessen the frequency and intensity of attacks and prevent long-term complications, including amyloidosis.

The primary pharmaceuticals for familial Mediterranean fever include colchicine, interleukin-1 inhibitors, and anti-IL-6 drugs. Colchicine is a medication that aids in reducing inflammation and preventing flare-ups in conditions such as gout and other inflammatory disorders. It can be administered orally or via injection and is utilized by various end users, including hospitals, clinical diagnostic laboratories, and others.

Tariffs have affected the familial mediterranean fever pharmaceuticals market by increasing the cost of imported active pharmaceutical ingredients and biologic components used in colchicine and interleukin inhibitor therapies. These impacts have been most pronounced in biologic drug segments, particularly in north america and europe where production depends on globally sourced inputs. Asia-pacific manufacturers have experienced supply chain disruptions and pricing pressure due to import reliance. However, tariffs have encouraged regional biologics manufacturing and localized API production, supporting long-term treatment availability.

The familial mediterranean fever pharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides familial mediterranean fever pharmaceuticals market statistics, including familial mediterranean fever pharmaceuticals industry global market size, regional shares, competitors with a familial mediterranean fever pharmaceuticals market share, detailed familial mediterranean fever pharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the familial mediterranean fever pharmaceuticals industry. This familial mediterranean fever pharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The familial mediterranean fever pharmaceuticals market size has grown strongly in recent years. It will grow from $1.72 billion in 2025 to $1.81 billion in 2026 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to established effectiveness of colchicine, genetic prevalence in mediterranean populations, limited alternative therapies, increased disease awareness, improved diagnostic criteria.

The familial mediterranean fever pharmaceuticals market size is expected to see strong growth in the next few years. It will grow to $2.21 billion in 2030 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to rising diagnosis rates outside endemic regions, growing adoption of biologics, expansion of orphan drug programs, improved genetic screening, increasing focus on long-term complication prevention. Major trends in the forecast period include continued reliance on colchicine therapy, increasing use of interleukin-1 inhibitors, expansion of biologic treatments for resistant FMF, growing focus on preventing amyloidosis, improved genetic diagnosis supporting early treatment.

The increasing adoption of gene therapy is anticipated to propel the growth of the familial Mediterranean fever (FMF) pharmaceuticals market in the coming years. Gene therapy is a medical strategy that alters or replaces defective genes to treat or prevent diseases at the genetic level. The growth of gene therapy is fueled by advancements in genetic engineering, which allow precise targeting and correction of genetic disorders, offering potential cures for diseases that were previously difficult or impossible to treat. Gene therapy influences the familial Mediterranean fever (FMF) pharmaceuticals market by addressing the underlying mutations in the MEFV (Mediterranean fever) gene, potentially providing a long-term or permanent solution rather than merely managing symptoms. For example, in July 2024, the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit organization, reported that 76 gene therapy trials were initiated in the second quarter of 2024, marking a 25% increase from the previous quarter. Consequently, the expansion of gene therapy is driving the growth of the familial Mediterranean fever (FMF) pharmaceuticals market.

Major companies in the familial Mediterranean fever pharmaceuticals market are concentrating on targeted biologic therapies, including dual interleukin-1 (IL-1a and IL-1B) blockade strategies and orphan drug designation pathways, to provide sustained disease remission and broaden treatment options for patients with autoinflammatory disorders. Dual interleukin-1 blockade strategies utilize heterodimeric hybrid proteins that simultaneously bind with high affinity to both IL-1a and IL-1B cytokines, effectively inhibiting the inflammatory cascade that underlies disease progression in familial Mediterranean fever and related conditions. For example, in November 2024, R-Pharm Group, a Russia-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for Goflikicept, a novel heterodimeric hybrid protein targeting both IL-1a and IL-1B, for the treatment of familial Mediterranean fever (FMF) and idiopathic recurrent pericarditis (IRP). The company completed Phase 2/3 clinical trials for IRP and obtained marketing authorization in Russia, while advancing a Phase 2 study for FMF across Turkey, Russia, and Armenia, positioning IL-1 blockade as a leading approach for achieving sustained remission in autoinflammatory diseases.

In January 2024, Swedish Orphan Biovitrum AB, a Sweden-based producer of Interleukin-1 inhibitors, formed a partnership with Acino International AG. The collaboration allows Acino to exclusively distribute Sobi's specialized treatments for rare diseases in Kazakhstan, increasing access to innovative therapies. Acino International AG is a Switzerland-based pharmaceutical firm focused on developing, manufacturing, and distributing high-quality generic and specialty medicines.

Major companies operating in the familial mediterranean fever pharmaceuticals market are Novartis International AG, Swedish Orphan Biovitrum AB, Granules Pharmaceuticals Inc., Hikma Pharmaceuticals plc, Camber Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Amgen Inc., Indena S.p.A., Harman Finochem, Alchem International, Honour Lab Ltd., Maithri Drugs Pvt. Ltd., Vital Laboratories Pvt. Ltd., Enomark Biotech Pvt. Ltd., Gonane Pharma, Ennature Biopharma, R-Pharm Group, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Lupin Limited

Middle East was the largest region in the familial mediterranean fever pharmaceuticals market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the familial mediterranean fever pharmaceuticals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the familial mediterranean fever pharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The familial mediterranean fever pharmaceuticals market consists of sales of NSAIDs, corticosteroids, immunosuppressants, disease-modifying antirheumatic drugs, and pain management medications used to manage inflammation and prevent complications in familial mediterranean fever patients. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Familial Mediterranean Fever Pharmaceuticals Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses familial mediterranean fever pharmaceuticals market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for familial mediterranean fever pharmaceuticals ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The familial mediterranean fever pharmaceuticals market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Type: Colchicine; Interleukin-1 Inhibitors; Anti-IL-6 Drugs
• 2) By Route Of Administration: Oral; Injectable
• 3) By End Users: Hospitals; Clinical Diagnostic Laboratories; Other End Users
• Subsegments:
• 1) By Colchicine: Oral Colchicine; Intravenous Colchicine
• 2) By Interleukin-1 Inhibitors: Anakinra; Canakinumab; Rilonacept
• 3) By Anti-IL-6 Drugs: Tocilizumab; Off-Label IL-6 Receptor Antagonists; Refractory FMF Supportive IL-6 Modulation
• Companies Mentioned: Novartis International AG; Swedish Orphan Biovitrum AB; Granules Pharmaceuticals Inc.; Hikma Pharmaceuticals plc; Camber Pharmaceuticals Inc.; Teva Pharmaceutical Industries Ltd.; Amgen Inc.; Indena S.p.A.; Harman Finochem; Alchem International; Honour Lab Ltd.; Maithri Drugs Pvt. Ltd.; Vital Laboratories Pvt. Ltd.; Enomark Biotech Pvt. Ltd.; Gonane Pharma; Ennature Biopharma; R-Pharm Group; Sun Pharmaceutical Industries Ltd.; Dr. Reddy's Laboratories Ltd.; Lupin Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Familial Mediterranean Fever Pharmaceuticals Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Familial Mediterranean Fever Pharmaceuticals Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Familial Mediterranean Fever Pharmaceuticals Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Familial Mediterranean Fever Pharmaceuticals Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Continued Reliance On Colchicine Therapy
  • 4.2.2 Increasing Use Of Interleukin-1 Inhibitors
  • 4.2.3 Expansion Of Biologic Treatments For Resistant Fmf
  • 4.2.4 Growing Focus On Preventing Amyloidosis
  • 4.2.5 Improved Genetic Diagnosis Supporting Early Treatment

5. Familial Mediterranean Fever Pharmaceuticals Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Clinics
• 5.3 Rheumatology Centers
• 5.4 Genetic Disorder Clinics
• 5.5 Homecare Settings

6. Familial Mediterranean Fever Pharmaceuticals Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Familial Mediterranean Fever Pharmaceuticals Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Familial Mediterranean Fever Pharmaceuticals PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Familial Mediterranean Fever Pharmaceuticals Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Familial Mediterranean Fever Pharmaceuticals Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Familial Mediterranean Fever Pharmaceuticals Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Familial Mediterranean Fever Pharmaceuticals Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Familial Mediterranean Fever Pharmaceuticals Market Segmentation

• 9.1. Global Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Colchicine, Interleukin-1 Inhibitors, Anti-IL-6 Drugs
• 9.2. Global Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Injectable
• 9.3. Global Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Clinical Diagnostic Laboratories, Other End Users
• 9.4. Global Familial Mediterranean Fever Pharmaceuticals Market, Sub-Segmentation Of Colchicine, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral Colchicine, Intravenous Colchicine
• 9.5. Global Familial Mediterranean Fever Pharmaceuticals Market, Sub-Segmentation Of Interleukin-1 Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Anakinra, Canakinumab, Rilonacept
• 9.6. Global Familial Mediterranean Fever Pharmaceuticals Market, Sub-Segmentation Of Anti-IL-6 Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Tocilizumab, Off-Label IL-6 Receptor Antagonists, Refractory FMF Supportive IL-6 Modulation

10. Familial Mediterranean Fever Pharmaceuticals Market Regional And Country Analysis

• 10.1. Global Familial Mediterranean Fever Pharmaceuticals Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Familial Mediterranean Fever Pharmaceuticals Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Familial Mediterranean Fever Pharmaceuticals Market

• 11.1. Asia-Pacific Familial Mediterranean Fever Pharmaceuticals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Familial Mediterranean Fever Pharmaceuticals Market

• 12.1. China Familial Mediterranean Fever Pharmaceuticals Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Familial Mediterranean Fever Pharmaceuticals Market

• 13.1. India Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Familial Mediterranean Fever Pharmaceuticals Market

• 14.1. Japan Familial Mediterranean Fever Pharmaceuticals Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Familial Mediterranean Fever Pharmaceuticals Market

• 15.1. Australia Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Familial Mediterranean Fever Pharmaceuticals Market

• 16.1. Indonesia Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Familial Mediterranean Fever Pharmaceuticals Market

• 17.1. South Korea Familial Mediterranean Fever Pharmaceuticals Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Familial Mediterranean Fever Pharmaceuticals Market

• 18.1. Taiwan Familial Mediterranean Fever Pharmaceuticals Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Familial Mediterranean Fever Pharmaceuticals Market

• 19.1. South East Asia Familial Mediterranean Fever Pharmaceuticals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Familial Mediterranean Fever Pharmaceuticals Market

• 20.1. Western Europe Familial Mediterranean Fever Pharmaceuticals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Familial Mediterranean Fever Pharmaceuticals Market

• 21.1. UK Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Familial Mediterranean Fever Pharmaceuticals Market

• 22.1. Germany Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Familial Mediterranean Fever Pharmaceuticals Market

• 23.1. France Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Familial Mediterranean Fever Pharmaceuticals Market

• 24.1. Italy Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Familial Mediterranean Fever Pharmaceuticals Market

• 25.1. Spain Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Familial Mediterranean Fever Pharmaceuticals Market

• 26.1. Eastern Europe Familial Mediterranean Fever Pharmaceuticals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Familial Mediterranean Fever Pharmaceuticals Market

• 27.1. Russia Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Familial Mediterranean Fever Pharmaceuticals Market

• 28.1. North America Familial Mediterranean Fever Pharmaceuticals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Familial Mediterranean Fever Pharmaceuticals Market

• 29.1. USA Familial Mediterranean Fever Pharmaceuticals Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Familial Mediterranean Fever Pharmaceuticals Market

• 30.1. Canada Familial Mediterranean Fever Pharmaceuticals Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Familial Mediterranean Fever Pharmaceuticals Market

• 31.1. South America Familial Mediterranean Fever Pharmaceuticals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Familial Mediterranean Fever Pharmaceuticals Market

• 32.1. Brazil Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Familial Mediterranean Fever Pharmaceuticals Market

• 33.1. Middle East Familial Mediterranean Fever Pharmaceuticals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Familial Mediterranean Fever Pharmaceuticals Market

• 34.1. Africa Familial Mediterranean Fever Pharmaceuticals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Familial Mediterranean Fever Pharmaceuticals Market, Segmentation By Drug Type, Segmentation By Route Of Administration, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Familial Mediterranean Fever Pharmaceuticals Market Regulatory and Investment Landscape

36. Familial Mediterranean Fever Pharmaceuticals Market Competitive Landscape And Company Profiles

• 36.1. Familial Mediterranean Fever Pharmaceuticals Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Familial Mediterranean Fever Pharmaceuticals Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Familial Mediterranean Fever Pharmaceuticals Market Company Profiles
  • 36.3.1. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Swedish Orphan Biovitrum AB Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Granules Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Hikma Pharmaceuticals plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Camber Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Familial Mediterranean Fever Pharmaceuticals Market Other Major And Innovative Companies

• Teva Pharmaceutical Industries Ltd., Amgen Inc., Indena S.p.A., Harman Finochem, Alchem International, Honour Lab Ltd., Maithri Drugs Pvt. Ltd., Vital Laboratories Pvt. Ltd., Enomark Biotech Pvt. Ltd., Gonane Pharma, Ennature Biopharma, R-Pharm Group, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Lupin Limited

38. Global Familial Mediterranean Fever Pharmaceuticals Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Familial Mediterranean Fever Pharmaceuticals Market

40. Familial Mediterranean Fever Pharmaceuticals Market High Potential Countries, Segments and Strategies

• 40.1 Familial Mediterranean Fever Pharmaceuticals Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Familial Mediterranean Fever Pharmaceuticals Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Familial Mediterranean Fever Pharmaceuticals Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer